FIREFLY-1: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors
This study is testing an oral medication called tovorafenib to see how safe and effective it is for children and young adults with certain types of slow-growing brain tumors or advanced solid tumors. Researchers want to find a new treatment option for young patients whose tumors have specific genetic changes and have continued to grow after previous treatments.
This study is for pediatric patients who have a recurrent or growing low-grade brain or spinal cord tumor, or an advanced solid tumor with a specific genetic change like a BRAF or RAF alteration. Participants must have already tried at least one prior whole-body treatment, such as chemotherapy, and have measurable tumor growth on scans.
Participants will take the study medication by mouth and go through several study phases, including screening, regular treatment visits, safety check-ups, and long-term follow-up assessments. Your care team will closely monitor your health and how the tumor responds to the medication through imaging scans.
This study is currently recruiting patients at medical centers in locations such as San Francisco, California; Washington D.C.; and Chicago, Illinois.
- 1Tests an oral anti-cancer medicine called tovorafenib for children and young adults.
- 2Focuses on tumors with specific genetic changes that have grown after prior treatments.
- 3Currently recruiting patients at multiple locations in the United States.
Related video
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.